Latest Advances in the Role of JAK/STAT Signaling Pathway in Autoimmune Rheumatic Diseases

doi:10.12114/j.issn.1007-9572.2022.0275

Abstract

Abstract:

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is a ubiquitously expressed intracellular signal transduction pathway involved in cell proliferation, differentiation, apoptosis, immune regulation and other biological processes. Existing evidence indicates that continuous activation of this signaling pathway is closely related to the pathogenesis and clinical manifestations of many autoimmune rheumatic diseases. We reviewed the latest advances in mechanisms of JAK/STAT signal transduction, and the roles of the pathway in development of autoimmune rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and gout, suggesting that JAK/STAT signaling pathway may be a therapeutic target for autoimmune rheumatic diseases, which may offer new ideas and directions for clinical treatment.

Key words: Autoimmune diseases, Rheumatic diseases, JAK, STAT, Arthritis, rheumatoid, Lupus erythematosus, systemic, Gout, Review

摘要：

Janus激酶/信号转导和转录激活子（JAK/STAT）信号通路是一种普遍表达的细胞内信号转导通路，参与细胞增殖、分化、凋亡和免疫调节等生物学过程。目前的研究证实该信号通路的持续激活与许多风湿免疫性疾病的发病及相关临床表现的发生密切相关。本文阐述了JAK/STAT信号通路的作用机制及其在类风湿关节炎、系统性红斑狼疮、痛风等风湿免疫性疾病发生、发展中的作用，提示JAK/STAT信号通路可作为风湿免疫性疾病的治疗靶点，为临床治疗提供新的思路与方向。

关键词: 自身免疫疾病, 风湿性疾病, Janus激酶, 信号转导子和转录激活子, 关节炎，类风湿, 红斑狼疮，系统性, 痛风, 综述

Fanni XIAO,Yufeng QING,Quanbo ZHANG. Latest Advances in the Role of JAK/STAT Signaling Pathway in Autoimmune Rheumatic Diseases[J]. Chinese General Practice, 2022, 25(17): 2159-2164. DOI: 10.12114/j.issn.1007-9572.2022.0275.
肖凡妮,青玉凤,张全波. JAK/STAT信号通路在风湿免疫性疾病中作用的研究进展[J]. 中国全科医学, 2022, 25(17): 2159-2164. DOI: 10.12114/j.issn.1007-9572.2022.0275.

Figures/Tables 2

References 37

[1]	GAO Q W，LIANG X W，SHAIKH A S，et al. JAK/STAT signal transduction：promising attractive targets for immune，inflammatory and hematopoietic diseases[J]. Curr Drug Targets，2018，19（5）：487-500. DOI：10.2174/1389450117666161207163054.
[2]	XIN P，XU X Y，DENG C J，et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol，2020，80：106210. DOI：10.1016/j.intimp.2020.106210.
[3]	GLADMAN D，RIGBY W，AZEVEDO V F，et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors[J]. N Engl J Med，2017，377（16）：1525-1536. DOI：10.1056/NEJMoa1615977.
[4]	VAN DER HEIJDE D，DEODHAR A，WEI J C，et al. Tofacitinib in patients with ankylosing spondylitis：a phaseⅡ，16-week，randomised，placebo-controlled，dose-ranging study[J]. Ann Rheum Dis，2017，76（8）：1340-1347. DOI：10.1136/annrheumdis-2016-210322.
[5]	VAN DER HEIJDE D，BARALIAKOS X，GENSLER L S，et al. Efficacy and safety of filgotinib，a selective Janus kinase 1 inhibitor，in patients with active ankylosing spondylitis（TORTUGA）：results from a randomised，placebo-controlled，phase 2 trial[J]. Lancet，2018，392（10162）：2378-2387. DOI：10.1016/S0140-6736(18)32463-2.
[6]	VAN DER HEIJDE D，SONG I H，PANGAN A L，et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis（SELECT-AXIS 1）：a multicentre，randomised，double-blind，placebo-controlled，phase 2/3 trial[J]. Lancet，2019，394（10214）：2108-2117. DOI：10.1016/S0140-6736(19)32534-6.
[7]	O'SHEA J J，SCHWARTZ D M，VILLARINO A V，et al. The JAK-STAT pathway：impact on human disease and therapeutic intervention[J]. Annu Rev Med，2015，66：311-328. DOI：10.1146/annurev-med-051113-024537.
[8]	OWEN K L，BROCKWELL N K，PARKER B S. JAK-STAT signaling：a double-edged sword of immune regulation and cancer progression[J]. Cancers，2019，11（12）：2002. DOI：10.3390/cancers11122002.
[9]	HAMMARÉN H M，VIRTANEN A T，RAIVOLA J，et al. The regulation of JAKs in cytokine signaling and its breakdown in disease[J]. Cytokine，2019，118：48-63. DOI：10.1016/j.cyto.2018.03.041.
[10]	MALEMUD C J. The role of the JAK/STAT signal pathway in rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis，2018，10（5/6）：117-127. DOI：10.1177/1759720X18776224.
[11]	SCHETT G，EMERY P，TANAKA Y，et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis：current evidence and future directions[J]. Ann Rheum Dis，2016，75（8）：1428-1437. DOI：10.1136/annrheumdis-2016-209201.
[12]	YOU H X，XU D，ZHAO J L，et al. JAK inhibitors：prospects in connective tissue diseases[J]. Clin Rev Allergy Immunol，2020，59（3）：334-351. DOI：10.1007/s12016-020-08786-6.
[13]	ZHANG A，LEE Y C. Mechanisms for joint pain in rheumatoid arthritis（RA）：from cytokines to central sensitization[J]. Curr Osteoporos Rep，2018，16（5）：603-610. DOI：10.1007/s11914-018-0473-5.
[14]	BOYDEN S D，HOSSAIN I N，WOHLFAHRT A，et al. Non-inflammatory causes of pain in patients with rheumatoid arthritis[J]. Curr Rheumatol Rep，2016，18（6）：30. DOI：10.1007/s11926-016-0581-0.
[15]	BARAL P，UDIT S，CHIU I M. Pain and immunity：implications for host defence[J]. Nat Rev Immunol，2019，19（7）：433-447. DOI：10.1038/s41577-019-0147-2.
[16]	TAYLOR P C，KEYSTONE E C，VAN DER HEIJDE D，et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis[J]. N Engl J Med，2017，376（7）：652-662. DOI：10.1056/nejmoa1608345.
[17]	CECCHINATO V，D'AGOSTINO G，RAELI L，et al. Redox-mediated mechanisms fuel monocyte responses to CXCL12/HMGB1 in active rheumatoid arthritis[J]. Front Immunol，2018，9：2118. DOI：10.3389/fimmu.2018.02118.
[18]	WALLACE D J，FURIE R A，TANAKA Y，et al. Baricitinib for systemic lupus erythematosus：a double-blind，randomised，placebo-controlled，phase 2 trial[J]. Lancet，2018，392（10143）：222-231. DOI：10.1016/S0140-6736(18)31363-1.
[19]	LI Y P，HIGGS R E，HOFFMAN R W，et al. A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus[J]. PLoS One，2019，14（12）：e0225651. DOI：10.1371/journal.pone.0225651.
[20]	SHAO W H，SHU D H，ZHEN Y X，et al. Prion-like aggregation of mitochondrial antiviral signaling protein in lupus patients is associated with increased levels of type Ⅰ interferon[J]. Arthritis Rheumatol，2016，68（11）：2697-2707. DOI：10.1002/art.39733.
[21]	ALUNNO A，PADJEN I，FANOURIAKIS A，et al. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus：integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent[J]. Cells，2019，8（8）：E898. DOI：10.3390/cells8080898.
[22]	DALBETH N，CHOI H K，JOOSTEN L A B，et al. Gout[J]. Nat Rev Dis Primers，2019，5（1）：69. DOI：10.1038/s41572-019-0115-y.
[23]	SUN Y，ABBONDANTE S，KARMAKAR M，et al. Neutrophil caspase-11 is required for cleavage of caspase-1 and secretion of IL-1β in Aspergillus fumigatus infection[J]. J Immunol，2018，201（9）：2767-2775. DOI：10.4049/jimmunol.1701195.
[24]	WINKLER S，RÖSEN-WOLFF A. Caspase-1：an integral regulator of innate immunity[J]. Semin Immunopathol，2015，37（4）：419-427. DOI：10.1007/s00281-015-0494-4.
[25]	TEMMOKU J，FUJITA Y，MATSUOKA N，et al. Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib[J]. Mod Rheumatol，2021，31（1）：270-275. DOI：10.1080/14397595.2020.1740410.
[26]	FRANCHIMONT N，WERTZ S，MALAISE M. Interleukin-6：an osteotropic factor influencing bone formation? [J]. Bone，2005，37（5）：601-606. DOI：10.1016/j.bone.2005.06.002.
[27]	CHEON Y H，KIM J Y，BAEK J M，et al. WHI-131 promotes osteoblast differentiation and prevents osteoclast formation and resorption in mice[J]. J Bone Miner Res，2016，31（2）：403-415. DOI：10.1002/jbmr.2612.
[28]	XU L J，ZHANG L X，ZHANG H J，et al. The participation of fibroblast growth factor 23（FGF23）in the progression of osteoporosis via JAK/STAT pathway[J]. J Cell Biochem，2018，119（5）：3819-3828. DOI：10.1002/jcb.26332.
[29]	DALAGIORGOU G，PIPERI C，ADAMOPOULOS C，et al. Mechanosensor polycystin-1 potentiates differentiation of human osteoblastic cells by upregulating Runx2 expression via induction of JAK2/STAT3 signaling axis[J]. Cell Mol Life Sci，2017，74（5）：921-936. DOI：10.1007/s00018-016-2394-8.
[30]	JETHWA H，BOWNESS P. The interleukin（IL）-23/IL-17 axis in ankylosing spondylitis：new advances and potentials for treatment[J]. Clin Exp Immunol，2016，183（1）：30-36. DOI：10.1111/cei.12670.
[31]	DAVIDSON S I，LIU Y，DANOY P A，et al. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese[J]. Ann Rheum Dis，2011，70（2）：289-292. DOI：10.1136/ard.2010.133322.
[32]	VEALE D J，MCGONAGLE D，MCINNES I B，et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis[J]. Rheumatology（Oxford），2019，58（2）：197-205. DOI：10.1093/rheumatology/key070.
[33]	MARIETTE X，CRISWELL L A. Primary Sjögren's syndrome[J]. N Engl J Med，2018，378（10）：931-939. DOI：10.1056/nejmcp1702514.
[34]	CHARRAS A，ARVANITI P，LE DANTEC C，et al. JAK inhibitors suppress innate epigenetic reprogramming：a promise for patients with Sjögren's syndrome[J]. Clin Rev Allergy Immunol，2020，58（2）：182-193. DOI：10.1007/s12016-019-08743-y.
[35]	GASPARINI G，COZZANI E，PARODI A. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis[J]. Cytokine，2020，125：154799. DOI：10.1016/j.cyto.2019.154799.
[36]	HIGASHIOKA K，KIKUSHIGE Y，AYANO M，et al. Generation of a novel CD₃₀⁺ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis[J]. Clin Exp Immunol，2020，201（3）：233-243. DOI：10.1111/cei.13477.
[37]	KITANAGA Y，IMAMURA E，NAKAHARA Y，et al. In vitro pharmacological effects of peficitinib on lymphocyte activation：a potential treatment for systemic sclerosis with JAK inhibitors[J]. Rheumatology（Oxford），2020，59（8）：1957-1968. DOI：10.1093/rheumatology/kez526.